CERS Cerus Corporation

USD 2.31 -0.08 -3.34728
Icon

Cerus Corporation (CERS) Stock Analysis and Price Targets

COMMON STOCK | Medical Devices | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 2.31

-0.08 (-3.35)%

USD 0.41B

0.71M

USD 3.63(+56.93%)

N/A

Icon

CERS

Cerus Corporation (USD)
COMMON STOCK | NSD
USD 2.31
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.41B

N/A

USD 2.31

Cerus Corporation (CERS) Stock Forecast

USD 3.63
(+56.93%)

Based on the Cerus Corporation stock forecast from 3 analysts, the average analyst target price for Cerus Corporation is USD 3.63 over the next 12 months. Cerus Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Cerus Corporation is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Cerus Corporation’s stock price was USD 2.31. Cerus Corporation’s stock price has changed by -2.12% over the past week, +36.69% over the past month and -19.23% over the last year.

No recent analyst target price found for Cerus Corporation
No recent average analyst rating found for Cerus Corporation

Company Overview Cerus Corporation

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to r...Read More

https://www.cerus.com

1220 Concord Avenue, Concord, CA, United States, 94520

625

December

USD

USA

Adjusted Closing Price for Cerus Corporation (CERS)

Loading...

Unadjusted Closing Price for Cerus Corporation (CERS)

Loading...

Share Trading Volume for Cerus Corporation Shares

Loading...

Compare Performance of Cerus Corporation Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CERS

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Cerus Corporation (Sector: Medical Devices )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM
DexCom Inc -0.19 (-0.17%) USD44.59B 72.34 57.12

ETFs Containing CERS

Symbol Name CERS's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Cerus Corporation (CERS) Stock

Based on ratings from 3 analysts Cerus Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on CERS's stock to indicate if its a good dividend stock.

Based on targets from 3 analysts, the average taret price for CERS is USD 3.63 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 2.5.

Unfortunately we do not have enough data on CERS's stock to indicate if its overvalued.

The last closing price of CERS's stock was USD 2.31.

The most recent market capitalization for CERS is USD 0.41B.

Based on targets from 3 analysts, the average taret price for CERS is projected at USD 3.63 over the next 12 months. This means that CERS's stock price may go up by +56.93% over the next 12 months.

We can't find any ETFs which contains Cerus Corporation's stock.

As per our most recent records Cerus Corporation has 625 Employees.

Cerus Corporation's registered address is 1220 Concord Avenue, Concord, CA, United States, 94520. You can get more information about it from Cerus Corporation's website at https://www.cerus.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...